Get the Stockscreener App
12.73
1.55%
-0.20
After Hours:
12.73
Myriad Genetics Inc Stock (MYGN) Forecast
The Myriad Genetics Inc (MYGN) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $15.23, representing a +19.68% increase from the current price of $12.73. The highest analyst price target is $21.95, and the lowest is $8.5182.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month MYGN Price Target
Average 11.54
(-9.36% Downside)
Is Myriad Genetics Inc (MYGN) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 43.17 | Neutral |
| STOCH(9,6) | 60.62 | Neutral |
| STOCHRSI(14) | 85.98 | Sell |
| MACD(12,26) | -0.4189 | Buy |
| ADX(14) | 28.41 | Sell |
| William %R | -38.94 | Neutral |
| CCI(14) | 12.73 | Neutral |
Buy: 1
Sell: 2
Neutral: 4
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
12.72
Buy
|
12.76
Sell
|
| MA20 |
13.02
Sell
|
13.00
Sell
|
| MA50 |
13.99
Sell
|
14.46
Sell
|
| MA100 |
18.25
Sell
|
17.02
Sell
|
| MA200 |
21.57
Sell
|
19.06
Sell
|
Buy: 1
Sell: 9
Neutral: 0
Summary: Sell
According to our latest analysis, MYGN could be considered a Strong Sell, with 17 technical analysis indicators signaling 2 Buy signals, 11 signaling Sell signals and 4 Neutral signals. This might not be a good time to consider opening new positions on MYGN, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 43.17 indicates that MYGN is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 60.62 indicates that MYGN is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 85.98 indicates that MYGN is oversold. This suggests that MYGN price is at or near the highest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 28.41 suggests a moderate trend in the market. While not exceptionally strong, it indicates that there is some directional movement occurring. You should pay attention to this trend but may also look for confirmation from other technical indicators or fundamental factors.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 12.73 indicates that MYGN is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term MYGN price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Myriad Genetics Inc financial reports and earnings history, Myriad Genetics Inc (MYGN) stock could reach $10.55 by 2030, $4.3564 by 2040 and $10.70 by 2050. See the projected annual prices until 2050 of the Myriad Genetics Inc stock below:
- Myriad Genetics Inc (MYGN) is expected to reach an average price of $5.6409 in 2035, with a high prediction of $6.9404 and a low estimate of $1.3699. This indicates an $-55.69% rise from the last recorded price of $12.73.
- Myriad Genetics Inc (MYGN) stock is projected to chart a bullish course in 2040, with an average price target of $1.8163, representing an $-85.73% surge from its current level. The forecast ranges from a conservative $1.0936 to a sky-high $4.3564.
- Our analysts predict Myriad Genetics Inc (MYGN) to jump -40.96% by 2045, soaring from $6.6428 to an average price of $7.5163, potentially reaching $7.0718. While $6.6428 is the low estimate, the potential upside is significant.
- Myriad Genetics Inc (MYGN) stock is expected to climb by 2050, reaching an average of $9.3546, a $-26.52% jump from its current level. However, a wide range of estimates exists, with high and low targets of $10.70 and $11.44, respectively, highlighting the market's uncertainty.
Myriad Genetics Inc Stock (MYGN) Year by Year Forecast
Myriad Genetics Inc Stock (MYGN) Price Forecast for 2025
Myriad Genetics Inc Stock (MYGN) is expected to reach an average price of $11.54 in 2025, with a high prediction of $21.95 and a low estimate of $1.1248. This indicates an -9.36% fall from the last recorded price of $12.73.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| March, 2025 | $8.8882 | $8.5182 | $21.95 | -30.18% |
| April, 2025 | $5.9726 | $1.1248 | $10.54 | -53.08% |
| May, 2025 | $7.0681 | $3.9614 | $8.1703 | -44.48% |
| June, 2025 | $6.7036 | $5.2447 | $8.1036 | -47.34% |
| July, 2025 | $4.1879 | $3.5741 | $8.9193 | -67.10% |
| August, 2025 | $3.5234 | $2.5669 | $4.7768 | -72.32% |
| September, 2025 | $4.2789 | $3.1648 | $4.7389 | -66.39% |
| October, 2025 | $4.5233 | $3.9433 | $7.1567 | -64.47% |
| November, 2025 | $5.2088 | $3.9199 | $6.121 | -59.08% |
| December, 2025 | $4.7032 | $3.9754 | $7.1132 | -63.05% |
Myriad Genetics Inc Stock (MYGN) Price Forecast for 2026
The predicted value for Myriad Genetics Inc (MYGN) in 2026 is set at an average of $17.18. Estimates vary from a peak of $29.58 to a trough of $4.772, indicating an +34.94% surge from the present price of $12.73.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $10.03 | $4.772 | $11.07 | -21.22% |
| February, 2026 | $10.29 | $9.4375 | $12.42 | -19.13% |
| March, 2026 | $19.03 | $9.693 | $19.66 | +49.49% |
| April, 2026 | $23.70 | $17.24 | $23.95 | +86.21% |
| May, 2026 | $22.89 | $19.14 | $24.94 | +79.81% |
| June, 2026 | $20.60 | $19.39 | $26.41 | +61.78% |
| July, 2026 | $19.86 | $17.02 | $24.47 | +56.00% |
| August, 2026 | $22.24 | $18.57 | $22.59 | +74.74% |
| September, 2026 | $25.69 | $21.04 | $25.73 | +101.80% |
| October, 2026 | $27.04 | $22.27 | $28.66 | +112.45% |
| November, 2026 | $28.41 | $24.86 | $29.58 | +123.18% |
| December, 2026 | $24.98 | $23.48 | $29.55 | +96.27% |
Myriad Genetics Inc Stock (MYGN) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Myriad Genetics Inc (MYGN) is $17.43, with a high forecast of $25.79 and a low forecast of $9.0762. This indicates an +36.95% increase from the last price of $12.73.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $25.21 | $23.21 | $25.79 | +98.04% |
| February, 2027 | $20.81 | $20.37 | $25.40 | +63.44% |
| March, 2027 | $17.66 | $16.34 | $21.27 | +38.73% |
| April, 2027 | $20.62 | $16.98 | $21.27 | +61.94% |
| May, 2027 | $18.01 | $16.48 | $20.89 | +41.48% |
| June, 2027 | $15.58 | $15.35 | $20.36 | +22.35% |
| July, 2027 | $18.14 | $15.26 | $20.67 | +42.50% |
| August, 2027 | $14.95 | $14.56 | $19.40 | +17.41% |
| September, 2027 | $16.14 | $11.98 | $16.35 | +26.79% |
| October, 2027 | $9.6062 | $9.0762 | $15.82 | -24.54% |
| November, 2027 | $12.75 | $9.7451 | $12.94 | +0.17% |
| December, 2027 | $20.75 | $12.06 | $21.32 | +62.97% |
Myriad Genetics Inc Stock (MYGN) Price Forecast for 2028
In 2028, Myriad Genetics Inc (MYGN) is projected to reach an average price of $14.16, with a high projection of $21.06 and a low estimate of $7.2602. This indicates an +11.25% rise from the last price of $12.73.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $14.99 | $14.79 | $21.06 | +17.77% |
| February, 2028 | $12.29 | $11.23 | $16.71 | -3.48% |
| March, 2028 | $13.99 | $11.37 | $14.31 | +9.91% |
| April, 2028 | $12.93 | $8.6403 | $15.44 | +1.55% |
| May, 2028 | $8.9713 | $8.8013 | $14.30 | -29.53% |
| June, 2028 | $13.72 | $7.2602 | $13.76 | +7.75% |
| July, 2028 | $12.05 | $11.57 | $15.09 | -5.32% |
| August, 2028 | $14.68 | $11.26 | $17.33 | +15.29% |
| September, 2028 | $16.81 | $14.22 | $17.51 | +32.07% |
| October, 2028 | $12.81 | $11.83 | $17.23 | +0.61% |
| November, 2028 | $16.99 | $10.87 | $17.14 | +33.48% |
| December, 2028 | $16.78 | $15.13 | $17.81 | +31.79% |
Myriad Genetics Inc Stock (MYGN) Price Forecast for 2029
The 2029 price forecast for Myriad Genetics Inc Stock (MYGN) is $12.83 on average, with a high prediction of $18.07 and a low estimate of $7.5861. This represents an +0.77% increase from the previous price of $12.73.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $15.99 | $15.20 | $17.11 | +25.62% |
| February, 2029 | $11.38 | $10.08 | $16.12 | -10.63% |
| March, 2029 | $10.32 | $8.844 | $12.03 | -18.91% |
| April, 2029 | $8.2884 | $8.2184 | $11.32 | -34.89% |
| May, 2029 | $10.24 | $7.5861 | $13.15 | -19.54% |
| June, 2029 | $13.06 | $9.9016 | $13.70 | +2.58% |
| July, 2029 | $13.00 | $11.64 | $16.01 | +2.15% |
| August, 2029 | $15.30 | $11.06 | $16.76 | +20.17% |
| September, 2029 | $16.66 | $14.67 | $17.68 | +30.90% |
| October, 2029 | $16.23 | $14.55 | $17.70 | +27.48% |
| November, 2029 | $12.52 | $12.23 | $16.27 | -1.62% |
| December, 2029 | $10.92 | $9.02 | $18.07 | -14.22% |
Myriad Genetics Inc Stock (MYGN) Price Forecast for 2030
Myriad Genetics Inc Stock (MYGN) is expected to reach an average price of $15.72 in 2030, with a high forecast of $31.13 and a low forecast of $0.3058. This signifies an +23.48% surge from the last price of $12.73.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $7.0187 | $6.0332 | $10.55 | -44.86% |
| February, 2030 | $8.8297 | $5.1142 | $11.40 | -30.64% |
| March, 2030 | $30.17 | $8.3975 | $31.13 | +137.00% |
| April, 2030 | $6.6817 | $5.2517 | $30.27 | -47.51% |
| May, 2030 | $11.98 | $6.3895 | $14.49 | -5.93% |
| June, 2030 | $15.64 | $10.90 | $16.59 | +22.87% |
| July, 2030 | $8.6702 | $3.5147 | $18.43 | -31.89% |
| August, 2030 | $10.86 | $7.9633 | $11.11 | -14.68% |
| September, 2030 | $11.78 | $8.1231 | $12.25 | -7.48% |
| October, 2030 | $3.1209 | $3.0429 | $13.78 | -75.48% |
| November, 2030 | $3.7881 | $0.3058 | $4.0187 | -70.24% |
| December, 2030 | $4.0371 | $2.6949 | $2.5904 | -68.29% |
1.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):